Effects of Netarsudil and Timolol on Retinal Blood Vessel Density and Visual Acuity

Exclusion Criteria

• •Subjects must have a diagnosis of OAG (including pigmentary or pseudoexfoliative) or OHT in 1 or both eyes. Subjects must not have ocular diseases to be included in the normal group.
• •Subjects must have a diagnosis of OAG (including pigmentary or pseudoexfoliative) or OHT in 1 or both eyes. Subjects must not have ocular diseases to be included in the normal group.
• •Subjects who are treatment-naïve must meet the following Intraocular Pressure (IOP) requirements at Visit 1 (Screening), and pretreated subjects must meet the following IOP requirements at Visit 2 (End of Washout):Intraocular pressure ≥ 20 mmHg in at least 1 eye and ≤ 30 mmHg in both eyes.
• •Subjects participating in any drug or device clinical investigation within 30 days prior to Visit 1 (Screening) for subjects requiring a washout period, or 30 days prior to Visit 3 (Randomization, Week 1) for treatment naïve subjects.
• •Subjects who anticipate participating in any other drug or device clinical investigation within the duration of this study.
• •Subjects with a history or presence of chronic generalized systemic disease that the Investigator feels might increase the risk to the subject or confound the results of the study.
• •Female subjects who are pregnant or breastfeeding.
• •Subjects currently taking systemic B-adrenergic antagonists.
• •Subjects with an anticipated need to initiate or modify medication (systemic or topical) that is known to affect IOP (eg, α-adrenergic agonists, calcium channel blockers, Angiotensin Converting Enzyme \[ACE\] inhibitors, and angiotensin II receptor blockers).
• •Subjects with known hypersensitivity or contraindications to netarsudil or any of the ingredients in the study drugs.
• •Subjects with known hypersensitivity or contraindications to timolol maleate or other adrenergic receptor antagonists or any of the ingredients in the study drugs.
• •Subjects who are expected to require treatment with ocular or systemic corticosteroids.
• •Subjects who are in need of any other topical or systemic treatment of OAG or OHT.
• •Subjects who are unable to discontinue contact lens use during and for 15 minutes following instillation of study drug and for 24 hours before check-in to and during each study visit.
• •Subjects with a central corneal thickness greater than 600 um in either eye.
• •Subjects with any condition that prevents reliable applanation tonometry (eg, significant corneal surface abnormalities) in either eye.
• •Subjects with advanced glaucoma.
• •Subjects with any condition that prevents clear visualization of the fundus in either eye.
• •Subjects who are monocular.
• •Subjects with previous or active corneal disease in either eye.
• •Subjects with current or a history of severe dry eye in either eye.
• •Subjects with active optic disc hemorrhage in either eye.
• •Subjects with current or a history of central/branch retinal vein or artery occlusion in either eye.
• •Subjects with current or a history of macular edema in either eye.
• •Subjects with very narrow angles (3 quadrants with less than Grade 2 according to Shaffer's anterior chamber angle grading system) and subjects with angle closure, congenital, and secondary glaucoma, and subjects with history of angle closure in either eye.
• •Subjects with a diagnosis of a clinically significant or progressive retinal disease (eg, diabetic retinopathy, macular degeneration) in either eye.
• •Subjects with any intraocular infection or inflammation in either eye within 3 months prior to Visit 1 (Screening).
• •Subjects with a history of ocular laser surgery in either eye within the 3 months prior to Visit 1 (Screening).
• •Subjects with a history of incisional ocular surgery or severe trauma in either eye within 3 months prior to Visit 1 (Screening).